Vera — Revenue-Integrity Layer for Veterinary Practices

§01

Why now

Four forces converge on the same 24 months: the money is there, the people aren't, the technology just crossed the threshold, and the buyers are consolidating into reachable groups.

The market Sourced

Big, growing, recession-resistant

US pet spend hit US$158B in 2025 (~95M pet households), heading to US$165B in 2026; veterinary care is the second-largest category.^[S1] Australia mirrors it at launch scale: A$21.3B total pet spend, 73% of households with a pet, and a A$5.7B veterinary-services industry.^[A1] [A2]

The workforce Sourced

A documented staffing crisis

Up to 50% of vets report burnout, over 25% quit each year, and the US faces a ~15,000-vet shortfall by 2030. Vets spend 1–2 hrs/day on documentation — "pajama time."^[S3] [S6] Australia is in its eighth year of veterinary shortage: 37% of vacancies take 12+ months to fill, average time-to-fill has tripled since 2014, and ~30% of vets intend to leave within five years.^[A4]

The technology Sourced

Ambient AI crossed the adoption line

~44 vet scribes in market and a category leader giving documentation away free is proof of demand — and proof the scribe itself is a commodity. The unclaimed layer is what the scribe's structured output makes possible.^[S4] [S6]

The buyers Sourced

Consolidation created two markets

Corporate/PE ownership of US clinics went from ~8% (2011) to ~50% (2025); PE deployed US$50B+ into the sector 2017–23, and Chewy acquired Modern Animal in April 2026. Independents still run ~51% of sites — so the go-to-market must be dual.^[S11]

Corporate & PE share of US veterinary clinics

Sourced endpoints

Two sourced endpoints; path between them interpolated. 25% of general practices and 75% of specialty practices are corporate-owned.^[S11]

View as table

Year	Corporate/PE share
2011	~8%
2025	~50%

Australia is the same movie, two reels earlier. The majors — Greencross (200+ clinics; Coles confirmed due diligence on a ~A$4bn acquisition, July 2026), VetPartners (270+ ANZ, EQT-owned, Sydney HQ), Apiam (80+, taken private Feb 2026), CVS Australia (51), Vets Central (72) — add to roughly 650–700 corporate sites, yet the top two groups hold only ~11% of industry revenue. Every major changed hands or structure in 2024–26: PE-run, ROI-literate, and buying.^[A6] The long tail is still independent — so the dual go-to-market works in both countries, and the enterprise targets are a train ride away, not a 14-hour flight.

§02

The four leaks

Sourced — US benchmarks

A practice that feels busy is quietly bleeding. None of this shows up as a line item — that's why owners underweight it. Each leak is independently sourced from US industry literature; validating the same rates on Australian P&Ls is an open item in §11.

Leak 01 — Missed charges Sourced

5–10% of revenue

Line items forgotten in a packed day and at staff handoff. AAHA found 17% of lab tests go unbilled; a documented solo practice lost ~8% (~US$40k/yr).^[S7]

Leak 02 — Missed calls Sourced

~25% of calls unanswered

Phones are synchronous and interrupt-driven; most callers never retry. A clinic can leave US$100k+/yr on the table — and ~80% of vet malpractice cases involve a communication breakdown.^[S9]

Leak 03 — No-shows Sourced

10–20% of booked slots

Weak reminders, no waitlist backfill. Every empty slot is fixed cost with zero revenue against it.^[S8]

Leak 04 — Lapsed recall Sourced

The compounding one

Preventive-care reminders trigger off invoiced items — so anything unbilled also silently exits the recall queue. Leak 01 causes Leak 04.^[S7] [S8]

The strategic insight: these aren't four problems. They're one problem — the practice has no reliable, real-time, structured record of what actually happened in each visit. A scribe produces exactly that record. That's why a scribe-first company, almost uniquely, can fix the money problem and not just the time problem.

§03

Run it on a practice

Illustrative model

Leak percentages are sourced; how much of each leak Vera actually recovers is an assumption until the pilot data exists — that's the point of the seed round. Drag the inputs and the ledger recomputes.

Currency

Practice gross revenue / yr

Leak scenario

Vera's share of recovered revenue

Modules

Missed-charge capture5–10% of revenue leaks at invoice ^[S7]

Missed-call & 24/7 booking~25% of inbound calls go unanswered ^[S9]

No-show waitlist backfill10–20% of slots no-show ^[S8]

Recall & reactivationreminders decoupled from invoicing ^[S8]

Recovered revenue / yr

Vera's fee

Practice keeps

Vera fee as % of practice revenue

Anchor: US$50k / US$70k / US$120k recoverable at a US$1.4M practice (conservative / midpoint / upside), scaled linearly with revenue — the sourced synthesis of the four leaks.^[S7–S9] Per-module split (45 / 25 / 15 / 15%) is an assumption. Recovery, not leak size, is what the seed round proves.

§04

The gap the scribe war leaves open

Every current player owns either the visit understanding (scribes), or the system of record (PIMS), or the phone (comms tools). Nobody owns the connective tissue that turns visit understanding into recovered revenue across whatever PIMS the practice already runs. PIMS incumbents are building the revenue features — but getting them means ripping out your PIMS, and that migration pain is our moat against them.

Player	Visit understanding	System of record	The phone	Cross-PIMS	Paid on recovery
Scribenote — US$8.2M seed (a16z), 6,000+ vets, free tier since Jun 2025 ^[S4]	●	—	—	◔	—
VetRec — YC; Bond Vet (55+ sites), IndeVets; adding comms/assistant ^[S5]	●	—	◔	◔	—
Scribe long tail — HappyDoc, ScribbleVet, CoVet, Otto, PupPilot, S10.ai… (~44 total) ^[S6]	●	—	—	◔	—
Heidi Health (AU) — ~$700M-valuation human-health scribe; veterinary vertical live, Greencross among displayed clients ^[A8]	●	—	—	◔	—
PIMS incumbents — IDEXX/ezyVet, Covetrus, Shepherd, Digitail: building charge capture & recall natively, but only inside their own system ^[S7] [S10]	◔	●	—	—	—
Comms point tools — Peerlogic, virtual receptionists, PetsApp ^[S9]	—	—	●	◔	—
Vera — the revenue-integrity layer on top of the existing PIMS	●	◔	●	●	●

● owns it◔ partial / emerging— absentVera row = target state, not current state

The Australian board state Sourced · Jul 2026

The scribe war has landed; the revenue layer hasn't

VetRec already prices in AUD (A$139–215/vet/mo). Heidi Health lists a veterinary vertical with Greencross among its displayed clients. Local vet scribes — Whippet Notes, Goldie, Vet Notes — compete on Australian data residency.^[A8] Nobody sells cross-PIMS revenue integrity priced on recovery, and vet-specific phone/missed-call AI is essentially un-localised for Australia.

The AU PIMS map Sourced

A cheaper moat-build than the US

ezyVet (IDEXX-owned, Auckland-born), Covetrus RxWorks & VisionVPM migrating to cloud Ascend, open-source OpenVPMS, IDEXX Neo, Provet Cloud, Digitail.^[A7] Integrating a half-dozen systems reaches most of the AU market — and every integration carries into ANZ and US expansion.

§05

Wedge → platform

Vera is not a scribe. Vera is the layer that makes your practice the money it already earned — the scribe is how you start.

Phase 1 · months 0–12

The scribe, with a spine

A genuinely excellent vet-specific ambient scribe: consent-first capture, SOAP notes, dental charts, discharge summaries — written back into the existing PIMS, not copy-pasted. Priced accessibly: its job is distribution, not margin.

The seed of the business is already here: structured charge suggestions. "You mentioned a fecal test, an injection and a nail trim — two aren't on the invoice." That line is why a vet keeps Vera over a free scribe.

Phase 2 · months 9–24

The revenue-integrity modules

Charge Capture · Missed-Call Recovery · No-Show Backfill · Recall & Reactivation. Each sold as an ROI module with clean before/after measurement baked in — because measured recovery is the Series A story.

Phase 3 · year 2+

Practice intelligence & the network

Benchmarking, inventory and demand forecasting, and an anonymized cross-practice data network that makes charge detection and recall timing smarter with every clinic — the flywheel a single-PIMS incumbent structurally can't match.

Consent-first UX — per-visit consent, jurisdiction-aware defaults Domain pipeline — vet terminology, species, drugs, three-way conversations Cross-PIMS layer — API where it exists, widget fallback where it doesn't Human-in-the-loop — suggest, never auto-bill Auditable — every suggestion traceable to the source utterance

§06

Market, built two ways

Bottoms-up on subscriptions and top-down on the value of the leaks — built independently so they can be stress-tested against each other. Australia is the launch market; the US is the scale market. The two lenses converge on a US software opportunity in the hundreds of millions per year.

Australia — the beachhead

Value of the leaks, AU Illustrative on sourced inputs

~A$285M/yr recoverable

~3,800 practices × ~A$1.5M average revenue (derived: A$5.7B ÷ 3,793 businesses) × the midpoint recoverable rate ≈ A$75k/practice. Software at 20–25% of recovered value ≈ A$57–71M/yr. Bottoms-up cross-check: 3,793 × A$10–15k platform ACV ≈ A$38–57M/yr.^[A2] [A5]

The honest ceiling Skeptic's note

AU proves it. The US pays for it.

A ~A$40–70M/yr software market is enough to prove recovery economics, NRR and the corporate-pilot motion — and too small to return a venture fund on its own. Leak rates are US-sourced benchmarks until validated on Australian P&Ls (§11). That's why the sequencing is AU launch → US scale, not AU-only.

United States — the scale market

Lens A — bottoms-up, subscription Illustrative

~US$350M/yr US SAM

Scribe-only is US$110–220M/yr and shrinking per-unit — the price war. Full-platform ACV of ~US$8–15k across 35,000 practices is the durable version: 35,000 × ~US$10k ≈ US$350M/yr.^[S2]

Lens B — top-down, value of the leaks Sourced inputs

~US$2.45B/yr recoverable

~US$70k midpoint recoverable per practice × 35,000 practices. Software capturing 20–25% of that value is a US$490–610M/yr opportunity from recovery alone — before scribe seats, comms or international.^[S7–S9]

The funnel, US view

BAR WIDTHS √-SCALED FOR VISIBILITY — READ THE NUMBERS

TAM value of the leaks, US

US$2.45B/yrrecoverable revenue

SAM software capture, US

US$350–610M/yrboth lenses converge here

SOM year 3 Illustrative

US$12–20M ARR~1,500–2,500 practices

Global TAM is materially larger — the US is the biggest single market but a minority of global veterinary spend; the vet AI-scribe segment alone is cited at >30% CAGR through 2028.^[S6]

§07

Business model & go-to-market

Targets — validate in diligence

Win the seat cheaply; monetize the value. The scribe is priced for distribution. The revenue modules are priced at ~20–30% of recovered revenue (or an ROI-anchored flat fee) — self-funding for the buyer, an order of magnitude more ACV than a scribe seat for us.

A free competitor can take the seat. They can't take a customer who's making $60k a year from the modules.

Evidence check (§11): practitioners already use buying language about scribes; nobody uses it about charge capture — leakage is absorbed as write-offs. So the revenue modules are sold to owners on audited before/after ROI, not marketed for inbound purchase. The scribe seat is the door; the pilot data is the pitch.

Metric	Target	Rationale
Blended ACV, maturing	~$6,000 → $8,000+	scribe seats + attached revenue modules
Gross margin	~75–80%	AI inference + support; improves with model efficiency
Blended CAC	~$3,000–6,000	self-serve scribe wedge + inside sales for modules
Payback	<12 months	revenue-share pricing accelerates it
Net revenue retention	>120%	land scribe → expand to modules and seats
LTV / CAC	>4×	cancelling Vera re-opens the leaks

Motion 1 — bottoms-up, independents

The mirror moment

Free/low-cost scribe as top of funnel; vet-to-vet referral in a tight-knit, forum-driven profession. After 60–90 days of scribe usage, show the practice its own data: "Vera heard $X in charges that never hit an invoice last month." That sentence is the upsell.

Launch in Australia: ~89% of industry revenue sits outside the top two groups, the community is tight (one AVA, ~3,800 practices), and referral loops are short.^[A6]

Motion 2 — enterprise, corporate groups

One signature, many sites

Corporate buyers want standardized revenue capture and analytics across locations — exactly the P&L language Vera speaks. Land 1–2 group pilots by Year 2. Locum vets — who rotate across clinics and PIMS — are a natural cross-practice beachhead.^[S3] [S11]

The Australian majors are concentrated, PE-run and reachable: VetPartners (EQT), Greencross (TPG → Coles pending), Apiam (Adamantem), CVS AU, Vets Central — ~650–700 sites behind five buyers, most within Sydney and Melbourne.^[A6]

§08

Illustrative trajectory

Illustrative — not projections of fact

Growth is powered less by logo count than by NRR — the same clinic paying 4–5× more as modules attach. The Australian launch phase, modeled in AUD; profitable from year one.

ARR build (AUD)

Blended ARPU ramps ~A$900 → ~A$1,200 → ~A$1,650/clinic/mo as revenue modules attach; ~15 → 60 → 120 ANZ clinics; gross margin ~75% → ~78%; net-positive every year. This is the Australian launch phase — the US scale market (§06) is upside beyond Year 3.

View as table

	Year 1	Year 2	Year 3
Paying clinics	~15	~60	~120
Blended ARPU / mo	~A$900	~A$1,200	~A$1,650
Revenue	~A$0.15M	~A$0.70M	~A$2.0M
Gross margin	~75%	~76%	~78%
Net profit	+A$12.5k	+A$60k	+A$180k

§09

Why this compounds

Cross-PIMS integrationhard, unglamorous, exactly what pure-model and single-PIMS players lack

Proprietary structured dataevery consult improves charge detection & recall timing

Value-based lock-incustomers making money churn less than users of a free feature

Workflow depththe phone, the invoice check, the recall engine — every role, not just the exam room

Distribution flywheelcheap wedge → data → better ROI → referrals → more practices

§10

Pre-mortem

The ways this dies, ranked — and what's engineered against each. Click a row for the mitigation.

HighScribe commoditization drags us into the price warmitigation

Never compete on scribe price — the scribe is CAC, not revenue. Differentiate at the seed with charge suggestions; monetize only the revenue layer. The entire pricing architecture exists so a free competitor taking scribe seats doesn't touch our economics.^[S4]

HighPIMS incumbents build or absorb the revenue featuresmitigation

Speed, plus the structural fact that their features require a PIMS migration nobody wants. Stay cross-PIMS — the get-the-benefit-without-the-rip-and-replace option — and consider partnering with PIMS that won't build it.^[S6] [S7]

HighCharge-capture accuracy isn't good enough to trustmitigation

Human-in-the-loop by design: suggest, never auto-bill. Full audit trail to the source utterance. Start where ground truth is cleanest — documented items vs. the invoice. The accuracy spike in §11 is scheduled before scale-up for exactly this reason.

Med–HighRecording-consent law, by state and by countrymitigation

Consent-first UX with per-visit consent, jurisdiction-aware defaults, and a manual-note fallback on refusal.^[S12] Australia sets a higher bar and a clearer answer: five of eight jurisdictions (NSW, WA, SA, TAS, ACT) require all-party consent and all eight restrict sharing recordings — so Vera ships all-party consent by design everywhere: scripted verbal consent per visit, timestamped in a consent log, signage plus intake disclosure, one-tap decline with unchanged service. This is exactly the pattern Heidi and Lyrebird normalized in Australian human health, aligned with OAIC's Oct 2024 AI-transcription guidance and Australian data residency.^[L1–L4] Desk scan complete; formal counsel review remains open (§11).

MedSMB churn and long enterprise cyclesmitigation

Dual motion: PLG independents offset enterprise cycle length; land-and-expand lifts NRR so growth doesn't depend on logo velocity.

MedROI attribution disputes — "did Vera really recover that?"mitigation

Rigorous before/after methodology with control periods baked into the product from day one. This isn't just dispute-defense — audited recovery data is the core Series A asset.

MedThe demand research is still partially openmitigation

The forum vector has moved from "cited secondhand" to "primary threads sampled" (§11) — but the structured 300–500-post coding pass and the ten problem interviews still gate any big GTM spend.

Low–MedAI inference cost compresses marginmitigation

Inference costs are trending down; revenue-share pricing cushions cost swings; margin structurally improves with model efficiency.^[S4]

The single most likely way this dies: we let ourselves become "another scribe," get dragged into the price war, and never earn the right to sell the revenue layer. Every structural choice in this proposal — pricing, product sequence, GTM — is engineered against that failure mode. Wedge, not product.

§11

What we haven't proven — and what just closed

Evidence board

A proposal is only as honest as its open-items list. Status as of July 2026:

The forum vector — moved from "cited secondhand" to primary evidence (4 Jul 2026). Live Reddit blocks automated reading, so the threads were mined via the public PullPush archive: 30 verbatim practitioner comments across ~19 threads (r/Veterinary, r/VetTech; 2022–2025), each with permalink, date and tag.^[F] VIN boards are member-login (unverified); Facebook groups not attempted; Australian communities not yet sampled. Full coded list in the research annex.

9

Doc pain

9

Scribe talk

4

Revenue leak

4

Phones

2

Willing-to-pay

2

Other

Hypothesis verdict: MIXED — and that's useful. "Documentation dominates mention volume" is supported: 17 of 30 items are documentation-related, and the pain surfaces unprompted even in relationship-advice threads. "Revenue leakage dominates willingness-to-pay" is refuted on this small sample (only 2 explicit WTP items, both attached to scribe/comms tools) — missed charges are framed as write-offs, blame and manual double-checking: a cost being absorbed, not a solution being shopped for. Both readings are actionable: the scribe wedge sits exactly where the live purchase conversation already is, and the revenue layer must be sold to owners on measured ROI, not bought inbound by practitioners — which raises the weight on the owner interviews and the audited before/after pilot data. Caveat: Reddit skews to US techs and associates; the actual buyer — the owner or practice manager — is under-represented.

"Negotiate for… an AI scribe for their notes. I've seen corp and most private clinics splurge for that."

[WTP] r/Veterinary · Feb 2025 · thread

"We have two people in hospital specifically whose major job is to check invoices prior to discharge… to make sure nothing was missed."

[REV-LEAK] r/VetTech · Jun 2024 · thread

"We don't collect. It's whoever inputs the charges fault. Looks very unprofessional to be like 'hey yeah, we undercharged you, please come back and pay us more…'"

[REV-LEAK] r/VetTech · Jun 2024 · thread

"The owner of the hospital, also a doctor, was literally behind FIVE YEARS on her notes."

[DOC-PAIN] r/VetTech · Jun 2023 · thread

"I used to be the front desk worker who stayed hours late every day… Our phones never stopped ringing, and clients were often frustrated and took it out on me."

[PHONE] r/VetTech · Aug 2024 · thread

"It stays recording the whole visit as well, so even when the client is waiting alone in the room it's recording… it definitely rubs me the wrong way."

[TOOL-CHURN] re: a competing scribe · r/VetTech · Apr 2025 · thread — why consent-first design is a feature, not a checkbox

Structured forum coding pass — 300–500 posts incl. VIN, practice-manager groups, AU communitiesfirst primary sample done (n=30, US-skewed); quantify pain-vs-WTP ratios properlypartial

Ten problem interviews — owners/managers + one corporate ops leadernow the critical test: do owners buy recovered revenue, at what share? Validate leak sizes against real P&Lsopen

Charge-capture accuracy spikedetect billables from a transcript at a precision vets trust — forum evidence shows editing fatigue is already a churn driveropen

Two PIMS integration spikes — one modern API (ezyVet / Ascend), one legacy (RxWorks / Cornerstone)sizes the hardest part of the moat; Ascend and RxWorks are the Australian install baseopen

Recording-consent legal revieweight-jurisdiction desk scan complete [L1–L4]; counsel confirmation + VPB NSW AI guidance pull pendingdesk done

AU leak-rate validationthe 5–10% / ~25% / 10–20% leak rates are US-sourced benchmarks; confirm on Australian practice data during pilotsopen

§12

The ask

RaisingA$750k seedfor 30% equity · A$2.5M post-money

FundsANZ scale + US entrygrowth capital — Vera is already profitable

Core Series A metric$ recoveredaudited average recovered revenue per practice

Use of funds

Illustrative

Engineering — the moat · 45% GTM · 25% Domain AI & data · 15% Ops & compliance · 10% Buffer · 5%

View as table

Allocation	%	What it buys
Engineering	45%	cross-PIMS integrations; first two revenue modules in production
GTM	25%	~120 ANZ clinics; first corporate pilot; US beachhead
Domain AI & data	15%	vet-specific tuning, accuracy, auditability
Ops & compliance	10%	consent handling; data governance
Buffer	5%	—

18-month milestones — the Series A gate

1 ~120 paying ANZ clinics via the scribe wedgetarget

2 Charge-capture + missed-call modules live, with audited before/after recovered-revenue datatarget

3 NRR >120% demonstrated on early cohortstarget

4 One to two corporate-group pilots signed and expandingtarget

5 Primary-research loop completed and folded into module priorityin progress

§13

Sources & method

Synthesized from nine analytical passes (market selection, voice-of-customer, sizing, competitive intel, product, unit economics, GTM, financial model, devil's advocate), each cross-checking the others. Market, workforce, competitive and leakage figures are sourced below; anything marked Illustrative is a modeling assumption, not a fact.

[S1] APPA 2026 State of the Industry — US pet industry $158B (2025), $165B projected (2026), ~95M pet households; vet care #2 category. americanpetproducts.org; petfoodindustry.com

[S2] AVMA / US Census & JAVMA (Dec 2025) — 34,296 practices (2023), ~+1.3%/yr; gross revenue per FTE vet ~$555k; ~15 patients/day. avma.org

[S3] AVMA / BLS via co.vet — ~127,000 practicing US vets; up to 50% burnout; >25% annual attrition; ~15,000-vet shortfall by 2030. co.vet; aavmc.org

[S4] Scribenote — $8.2M seed led by a16z (Sept 2024); 6,000+ vets; free tier (June 2025); ~44 competing scribes. siliconrepublic.com; globenewswire.com; scribenote.com

[S5] VetRec — Y Combinator; Bond Vet (55+ locations), IndeVets. ycombinator.com; vetrec.io

[S6] Competitive landscape — scribe long tail; 1–2 hrs/day documentation (Volk 2022); scribe segment >30% CAGR through 2028. veterinarybusinessadvisors.com; happydoc.ai; puppilot.co

[S7] Missed charges — 5–10% of revenue; AAHA: 17% of lab tests unbilled; $2M practice → ~$200k/yr. ksmcpa.com; dvm360.com; todaysveterinarybusiness.com

[S8] No-shows 10–20% of slots; recall the most under-exploited lever. software.idexx.com

[S9] Missed calls ~25%; small businesses lose ~$126k/yr; ~80% of vet malpractice involves communication breakdown. peerlogic.com; unicomcorp.com; puppilot.co

[S10] Inventory — 20–25% of expenses, 5–10% waste. vetsource.com; digitail.com

[S11] Consolidation — ~8% (2011) → ~50% (2025) corporate/PE; PE $50B+ (2017–23); Chewy → Modern Animal (Apr 2026). ctacquisitions.com; aaha.org; thenation.com

[S12] US consent & recording law — one/two/all-party variation; consent-every-visit best practice. pawfectnotes.com

Australian sources — researched 4 July 2026 (this document's own verification pass):

[A1] Animal Medicines Australia, Pets in Australia 2025 (Sep 2025) — A$21.3B total pet spend; 73% of households; 31.6M pets across ~7.7M households. animalmedicinesaustralia.org.au

[A2] IBISWorld, Veterinary Services in Australia (2025) — A$5.7B industry revenue; 3,793 businesses (+2.1% CAGR 2020–25); AVA echoes the practice count. Note: AMA's household-survey vet spend (A$1.9B) uses a different methodology and is not mixed with IBISWorld figures here. ibisworld.com; ava.com.au

[A3] Vets in Australia — 16,167 (IBISWorld forecast FY2025-26); NSW anchor: 4,986 registered (NSW Veterinary Practitioners Board, 30 Jun 2025). ibisworld.com; vpb.nsw.gov.au

[A4] AU workforce crisis — AVA Workforce Survey 2023/24 (Oct 2024): 36.8% of vet vacancies take 12+ months to fill (44% regional); Jobs & Skills Australia: time-to-fill 8 wks (2014) → 25 wks (2023); Professionals Australia (2022): 30% intend to leave within 5 yrs; Frontiers in Vet Science (2024, n=320): 60.2% considered leaving their practice area in the past year; AVA: 8th consecutive year of shortage. ava.com.au; jobsandskills.gov.au; pmc.ncbi.nlm.nih.gov

[A5] AU practice economics — average revenue/practice ~A$1.50M derived (A$5.7B ÷ 3,793; businesses ≠ clinic sites); A$400–600k revenue per FTE vet (ScaleSuite, undated — indicative only); gross margin 74–77% (ATO 2021 via Covetrus). scalesuite.com.au; software.covetrus.com

[A6] AU consolidation — Greencross: 200+ clinics, TPG-owned, Coles confirmed due diligence on a ~A$4bn acquisition (1 Jul 2026); VetPartners: 270+ ANZ+SG, EQT (completed Jan 2024), Sydney HQ; Apiam: 80+ clinics, Adamantem Capital, delisted Feb 2026; CVS Australia: 51 clinics (Sep 2025); Vets Central: 72. Revenue concentration (IBISWorld 2023): Greencross ~6.1%, VetPartners ~5%, remainder fragmented. insidefmcg.com.au; eqtgroup.com; apiam.com.au; cvsukltd.co.uk; vetscentral.com.au; vetsuppliersdirectory.com.au

[A7] AU/NZ PIMS — ezyVet (founded Auckland 2006; IDEXX acquired 2021, US$216M); Covetrus RxWorks & VisionVPM → cloud Ascend; OpenVPMS (Australian open-source); IDEXX Neo; Provet Cloud; Digitail. idexx.com; software.covetrus.com/apac; openvpms.org

[A8] AI scribes in AU — VetRec: AUD pricing A$139–215/vet/mo (vetrec.io/au); Heidi Health: veterinary vertical listed, Greencross among displayed client logos, ≈$138M raised / ~$700M valuation (heidihealth.com/en-au; medicalrepublic.com.au); Whippet Notes: AU vet scribe, AU/IE data residency, Ascend & RxWorks integrations (whippetnotes.com); Goldie, Vet Notes (competitor-cited). Vet-specific phone-AI: no localised AU player found.

[A9] AUD/USD ≈ 0.692 (2 Jul 2026). exchangerates.org.uk

Australian recording & privacy law — desk research 4 July 2026 (not legal advice; counsel review pending):

[L1] State surveillance law — all-party consent to record a private conversation: NSW (Surveillance Devices Act 2007 s7), WA (SDA 1998 s5), SA (SDA 2016 s4), TAS (Listening Devices Act 1991 s5), ACT (LDA 1992 s4). Participant recording lawful: VIC (SDA 1999 s6), QLD (Invasion of Privacy Act 1971 s43), NT (SDA 2007 s11) — but communication/publication of recordings is restricted in all eight jurisdictions, which makes covert-then-transcribe legally gray everywhere; all-party consent cures both. legislation.nsw.gov.au et al.; hamiltonlocke.com.au

[L2] Privacy Act 1988 (Cth) — ≤A$3M small-business exemption with carve-outs; vet clinics' status under the health-service definition unsettled (flag for counsel); the scribe vendor is an APP entity regardless. OAIC Guidance on privacy and commercially available AI products (Oct 2024) expressly covers transcription tools: PIA, transparency, no training on personal data without consent. oaic.gov.au

[L3] Vet board signals — Veterinary Practitioners Board of NSW lists an "AI-based Record Keeping and Note Taking" resource (updated ~Mar 2026; content to be pulled by counsel); state record-keeping guidelines: VIC Guideline 07, WA, SA (2024). vpb.nsw.gov.au; vetboard.vic.gov.au

[L4] Consent-practice precedent (human health) — Heidi & Lyrebird: per-visit verbal consent, timestamped consent logs, pre-notification, decline-with-unchanged-care; AIDH implementation sheet (Jun 2025); Safer Care Victoria ambient-scribe advisory (May 2025); Ahpra AI obligations (2024). heidihealth.com; lyrebirdhealth.com; digitalhealth.org.au; ahpra.gov.au

Forum vector — primary evidence, 4 July 2026:

[F] 30 verbatim practitioner comments across ~19 threads, r/Veterinary + r/VetTech (2022–2025), mined via the public PullPush archive after live Reddit blocked automated access; permalinks retained per item; vendor/SEO pages encountered in search were excluded as evidence. Verdict on the falsifiable hypothesis: MIXED — mention-volume clause supported, willingness-to-pay clause refuted at n=2. Known skews: US-centric, techs/associates over owners; VIN login-walled; AU communities unsampled. Full coded list: Module 8 research annex — forum-vector-primary-threads.md.